In one study [36] on nivolumab’s integration with chemotherapy for treating advanced/metastatic gastric, gastroesophageal junction cancer, and esophageal adenocarcinoma, the calculated number needed to treat (NNT) for improving the overall survival (OS), progression-free survival, and objective response rate (ORR) indicates significant patient benefits, especially noted in a subgroup with PD-L1 CPS ≥ 5, suggesting enhanced effectiveness in patients with higher PD-L1 expression. This evidence concerns the gene CD274 and esophageal adenocarcinoma.